Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines.

Patel A, Reuschel EL, Kraynyak KA, Racine T, Park DH, Scott VL, Audet J, Amante D, Wise MC, Keaton AA, Wong G, Villarreal DO, Walters J, Muthumani K, Shedlock DJ, de La Vega MA, Plyler R, Boyer J, Broderick KE, Yan J, Khan AS, Jones S, Bello A, Soule G, Tran KN, He S, Tierney K, Qiu X, Kobinger GP, Sardesai NY, Weiner DB.

J Infect Dis. 2018 Oct 10. doi: 10.1093/infdis/jiy537. [Epub ahead of print]

PMID:
30304515
2.

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.

Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser M, Kumar R, Weiner D, Csiki I, Bagarazzi ML.

Clin Cancer Res. 2019 Jan 1;25(1):110-124. doi: 10.1158/1078-0432.CCR-18-1763. Epub 2018 Sep 21.

PMID:
30242022
3.

Delineating the Cellular Mechanisms Associated with Skin Electroporation.

Schultheis K, Smith TRF, Kiosses WB, Kraynyak KA, Wong A, Oh J, Broderick KE.

Hum Gene Ther Methods. 2018 Aug;29(4):177-188. doi: 10.1089/hgtb.2017.105. Epub 2018 Aug 10.

PMID:
29953259
4.

In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.

Muthumani K, Griffin BD, Agarwal S, Kudchodkar SB, Reuschel EL, Choi H, Kraynyak KA, Duperret EK, Keaton AA, Chung C, Kim YK, Booth SA, Racine T, Yan J, Morrow MP, Jiang J, Lee B, Ramos S, Broderick KE, Reed CC, Khan AS, Humeau L, Ugen KE, Park YK, Maslow JN, Sardesai NY, Joseph Kim J, Kobinger GP, Weiner DB.

NPJ Vaccines. 2016 Nov 10;1:16021. doi: 10.1038/npjvaccines.2016.21. eCollection 2016.

5.

Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.

Morrow MP, Kraynyak KA, Sylvester AJ, Dallas M, Knoblock D, Boyer JD, Yan J, Vang R, Khan AS, Humeau L, Sardesai NY, Kim JJ, Plotkin S, Weiner DB, Trimble CL, Bagarazzi ML.

Clin Cancer Res. 2018 Jan 15;24(2):276-294. doi: 10.1158/1078-0432.CCR-17-2335. Epub 2017 Oct 30.

6.

Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody.

Muthumani K, Marnin L, Kudchodkar SB, Perales-Puchalt A, Choi H, Agarwal S, Scott VL, Reuschel EL, Zaidi FI, Duperret EK, Wise MC, Kraynyak KA, Ugen KE, Sardesai NY, Joseph Kim J, Weiner DB.

Cancer Immunol Immunother. 2017 Dec;66(12):1577-1588. doi: 10.1007/s00262-017-2042-7. Epub 2017 Aug 17.

7.

Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus.

Smith TRF, Schultheis K, Morrow MP, Kraynyak KA, McCoy JR, Yim KC, Muthumani K, Humeau L, Weiner DB, Sardesai NY, Broderick KE.

Vaccine. 2017 May 15;35(21):2840-2847. doi: 10.1016/j.vaccine.2017.04.008. Epub 2017 Apr 14.

8.

A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.

Walters JN, Ferraro B, Duperret EK, Kraynyak KA, Chu J, Saint-Fleur A, Yan J, Levitsky H, Khan AS, Sardesai NY, Weiner DB.

Mol Ther. 2017 Apr 5;25(4):976-988. doi: 10.1016/j.ymthe.2017.01.022. Epub 2017 Feb 22.

9.

Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100.

Morrow MP, Kraynyak KA, Sylvester AJ, Shen X, Amante D, Sakata L, Parker L, Yan J, Boyer J, Roh C, Humeau L, Khan AS, Broderick K, Marcozzi-Pierce K, Giffear M, Lee J, Trimble CL, Kim JJ, Sardesai NY, Weiner DB, Bagarazzi ML.

Mol Ther Oncolytics. 2016 Nov 30;3:16025. doi: 10.1038/mto.2016.25. eCollection 2016.

10.

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML.

Lancet. 2015 Nov 21;386(10008):2078-2088. doi: 10.1016/S0140-6736(15)00239-1. Epub 2015 Sep 17.

11.

A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.

Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, Seliga AM, Soule G, Morrow M, Kraynyak KA, Khan AS, Scott DP, Feldmann F, LaCasse R, Meade-White K, Okumura A, Ugen KE, Sardesai NY, Kim JJ, Kobinger G, Feldmann H, Weiner DB.

Sci Transl Med. 2015 Aug 19;7(301):301ra132. doi: 10.1126/scitranslmed.aac7462.

12.

Tapping the Potential of DNA Delivery with Electroporation for Cancer Immunotherapy.

Kraynyak KA, Bodles-Brakhop A, Bagarazzi M.

Curr Top Microbiol Immunol. 2017;405:55-78. doi: 10.1007/82_2015_431.

PMID:
25682101
13.

Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.

Yan J, Tingey C, Lyde R, Gorham TC, Choo DK, Muthumani A, Myles D, Weiner LP, Kraynyak KA, Reuschel EL, Finkel TH, Kim JJ, Sardesai NY, Ugen KE, Muthumani K, Weiner DB.

Cancer Gene Ther. 2014 Dec;21(12):507-17. doi: 10.1038/cgt.2014.56. Epub 2014 Nov 14.

PMID:
25394503
14.

Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant.

Kathuria N, Kraynyak KA, Carnathan D, Betts M, Weiner DB, Kutzler MA.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1607-19. doi: 10.4161/hv.22574. Epub 2012 Nov 1.

15.

Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH.

Vaccine. 2012 Oct 12;30(46):6541-6550. doi: 10.1016/j.vaccine.2012.08.049. Epub 2012 Sep 1.

16.

Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease.

Morello CS, Levinson MS, Kraynyak KA, Spector DH.

J Virol. 2011 Apr;85(7):3461-72. doi: 10.1128/JVI.02521-10. Epub 2011 Jan 26.

17.

Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.

Kraynyak KA, Kutzler MA, Cisper NJ, Khan AS, Draghia-Akli R, Sardesal NY, Lewis MG, Yan J, Weiner DB.

Vaccine. 2010 Feb 23;28(8):1942-51. doi: 10.1016/j.vaccine.2009.10.095.

18.

Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo.

Kutzler MA, Kraynyak KA, Nagle SJ, Parkinson RM, Zharikova D, Chattergoon M, Maguire H, Muthumani K, Ugen K, Weiner DB.

Gene Ther. 2010 Jan;17(1):72-82. doi: 10.1038/gt.2009.112. Epub 2009 Oct 22.

PMID:
19847203
19.

Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo.

Kraynyak KA, Kutzler MA, Cisper NJ, Laddy DJ, Morrow MP, Waldmann TA, Weiner DB.

Hum Gene Ther. 2009 Oct;20(10):1143-56. doi: 10.1089/hum.2009.025.

Supplemental Content

Loading ...
Support Center